Skip to main content
TipRanks
Go Ultimate75% OFF

SUSMED,Inc. (4263) AI Stock Analysis

0 Followers
JP:4263

SUSMED,Inc.

(TSE/TYO:4263)

Select Model
Rating:38Underperform
Price Target:JPY 237.00â–¼(-5.95% Downside)
Action:reiterated
Date:11/05/26

SUSMED scores near the low end of the range. The dominant drag is financial performance: deepening net losses (-¥383M) and record cash burn (-¥549M free cash flow) in FY2026, with operating expenses outpacing an otherwise strong 81% revenue rebound. The debt-free balance sheet and ¥4.07B equity cushion provide real downside protection and several years of runway, but equity is steadily being consumed. Technicals reinforce the caution, with the price far below all key moving averages and negative MACD confirming a sustained downtrend, though extremely low RSI and Stochastic readings suggest selling has become stretched. Valuation offers no anchor given negative earnings and no dividend. The investment case hinges on whether revenue can scale to cover the cost base before the balance sheet cushion erodes.

Positive Factors
Strong Revenue GrowthRapid revenue expansion indicates improving commercial traction and growing adoption of the company’s healthcare technology offerings. If sustained, this larger revenue base could spread fixed costs, support operating leverage, and strengthen the platform’s position over the next several quarters.
Negative Factors
Persistent Operating LossesLarge operating and net losses show that the current revenue base is not yet sufficient to cover the company’s cost structure. Continued losses could delay self-funded growth, require additional capital, and prevent the strong gross-margin profile from translating into sustainable earnings.

SUSMED,Inc. (4263) vs. iShares MSCI Japan ETF (EWJ)

-80%-60%-40%-20%0%20%40%JP:4263-71.94%EWJ+16.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
JPY 4.27B
Dividend Yield
―
Average Volume (3M)
155.37K
Price to Earnings (P/E)
-9.1
Beta (1Y)
1.01
Revenue Growth
42.52%
EPS Growth
-81.61%
Country
Japan
Employees
50
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

SUSMED,Inc. Business Overview & Revenue Model

Company Description

SUSMED,Inc. develops and sells therapeutic applications in Japan. It operates through DTx product business, and DTx platform business segments. The company develops smartphone based digital therapeutics applications for diseases with insomnia, breast...

SUSMED,Inc. Financial Statement Overview

Summary

Financials are weak overall. The income statement (score 25) shows persistent and widening losses, with a net loss of ¥383M in FY2026 despite revenue rebounding ~81% to ¥497M; operating costs are scaling faster than sales and the company has never reached operating profitability. Cash flow (score 18) is the biggest concern, with operating cash flow of -¥474M and free cash flow of -¥549M in FY2026, the worst on record and an accelerating burn. The balance sheet (score 72) is the offsetting strength: zero debt, a 0.0 debt-to-equity ratio, and ¥4.07B of equity provide meaningful runway, though equity has eroded from ¥4.87B in FY2023 as losses accumulate. Excellent ~96-97% gross margins highlight the asset-light model, but scale remains far too small to cover the cost base.

Income Statement

25Negative

Balance Sheet

72Positive

Cash Flow

18Very Negative
Financial statement breakdown
BreakdownTTMJun 2025Jun 2024Jun 2023Jun 2022Jun 2022
Income Statement
Total Revenue679.26M497.21M462.99M342.58M316.87M530.65M
Gross Profit650.78M479.82M450.72M330.85M306.50M522.67M
EBITDA-241.92M-319.99M-289.22M-350.22M-231.11M-43.99M
Net Income-465.37M-382.69M-298.40M-357.42M-233.48M-50.75M
Balance Sheet
Total Assets4.19B4.22B4.50B4.93B4.94B5.10B
Cash, Cash Equivalents and Short-Term Investments3.95B3.70B4.40B4.85B4.90B5.05B
Total Debt000000
Total Liabilities301.93M147.94M132.33M327.79M93.34M230.33M
Stockholders Equity3.89B4.07B4.37B4.60B4.85B4.87B
Cash Flow
Free Cash Flow0-548.50M-436.79M-240.04M-177.90M82.40M
Operating Cash Flow0-474.45M-432.48M-230.76M-165.28M100.59M
Investing Cash Flow0-228.13M-19.97M-8.53M-20.36M-18.19M
Financing Cash Flow02.75M3.67M37.37M3.46B62.36M

SUSMED,Inc. Technical Analysis

Technical Analysis SentimentNegative
Last Price252.00

Price Trends

50DMA378.42Negative
100DMA536.55Negative
200DMA726.12Negative

Market Momentum

MACD-40.95Positive
RSI16.15Positive
STOCH6.02Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4263, the sentiment is Negative. The current price of 252.00 is below the 20-day moving average (MA) of 319.65, below the 50-day MA of 378.42, and below the 200-day MA of 726.12, indicating a bearish trend. The MACD of -40.95 indicates Positive momentum. The RSI at 16.15 is Positive, neither overbought nor oversold. The STOCH value of 6.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4263.

SUSMED,Inc. Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

JP:4263 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
JP:2413JP:241379OutperformJPY 1.24T26.5411.33%1.20%9.48%2.08%
JP:4483JP:448372OutperformJPY 244.77B33.34―0.48%20.50%19.27%
JP:4438JP:443854NeutralJPY 2.34B-4.39――14.84%30.67%
JP:4480JP:448054NeutralJPY 67.05B38.4811.30%―21.01%10.15%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
JP:4263JP:426338UnderperformJPY 4.27B-9.13――42.52%-81.61%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%JP:4263JP:2413JP:4480JP:4438JP:4483Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
JP:4263 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
JP:4263SUSMED,Inc.252.00-658.00-72.31%
JP:2413M3 1832.00-805.80-30.55%
JP:4480Medley, Inc.2108.00-447.00-17.50%
JP:4438Welby Inc.274.00-57.00-17.22%
JP:4483JMDC Inc.3740.00-514.30-12.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 05, 2026